FDA Grants Breakthrough Therapy Designation to Merck’s Sacituzumab Tirumotecan for EGFR-Mutated NSCLC

Spur Therapeutics Unveils SPR301: A Novel Gene Therapy for GBA1-Linked Parkinson’s Disease

M | O | C Cancer Care & Research Centre Achieves CAR-T Therapy Milestone

Aptose Biosciences Collaborates with NCI to Advance Tuspetinib in Precision Medicine Trials for AML and MDS

Novartis and PTC Therapeutics Forge $2.9 Billion Partnership for Huntington’s Drug PTC518

HCG and Accenture Partner to Transform Cancer Care with Advanced AI

GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics, Expanding Molecular Imaging Leadership in Asia

Strand Life Sciences Unveils CancerSpot for Early Cancer Detection

Allink Biotherapeutics Secures $42 Million in Series A Financing to Accelerate Development of Next-Generation Oncology and Immunology Therapies

Apollo Cancer Centres Launch India’s First Lunglife Screening Programme for Early Detection of Lung Cancer

Agilus Diagnostics Unveils Claudin 18.2 Test: A Breakthrough in Cancer Care

Leqembi® Launched in South Korea for Early Alzheimer’s Disease Treatment

QIAGEN Expands QIAstat-Dx Operations with New Facility in Barcelona

SunAct Cancer Institute Partners with Abgentil Biomedical to Revolutionize Cancer Treatment in India

Dr. Reddy’s Launches Toripalimab in India for Advanced Nasopharyngeal Carcinoma

Home
/
update
/
details

QIAGEN Expands QIAstat-Dx Operations with New Facility in Barcelona

NextEdge Admin

29 Nov 2024

2 min 36 sec

QIAstat-Dx,multiplexing,PCR,Precision Medicine,Infectious diseases

QIAGEN announced plans to relocate its QIAstat-Dx operations in Barcelona to a new, state-of-the-art facility in Esplugues de Llobregat by early 2026. This move is part of a multi-year investment to enhance its syndromic testing solutions, including the QIAstat-Dx system, which identifies illnesses such as respiratory, gastrointestinal, and meningitis/encephalitis conditions.

The new 8,000-square-meter site will house Research & Development, Manufacturing, Sales, Marketing, Quality Assurance, and Regulatory Affairs. It will also serve as a hub for innovation in microfluidics and assay development. Designed for energy efficiency, the facility has achieved LEED Platinum Certification and will feature advanced digitalized production lines.

QIAstat-Dx utilizes cost-effective, single-use cartridges with multiplex real-time PCR technology to deliver results within an hour. The system has FDA-cleared panels for respiratory, gastrointestinal, meningitis, and encephalitis pathogens, alongside CE-marked panels under the European IVDR framework. QIAstat-Dx is also advancing into precision medicine, with partnerships with Eli Lilly and AstraZeneca focusing on genotyping for genomically targeted therapies.

Barcelona’s robust scientific ecosystem and local expertise—QIAstat-Dx originated from a Barcelona-based startup acquired by QIAGEN in 2018—make it an ideal location. The new site will expand diagnostic capabilities to address a broader range of pathogens, such as those causing urinary tract infections and blood culture identification, while supporting decentralized testing.

“QIAstat-Dx proved invaluable during COVID-19 and continues to address critical healthcare needs,” said Thierry Bernard, CEO of QIAGEN. "This expansion reinforces our commitment to advancing diagnostic solutions in infectious diseases and beyond." The facility will also support innovations in chronic diseases like neurodegenerative, metabolic, and inflammatory conditions, further strengthening QIAGEN’s diagnostic footprint.